You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Pulmonary arterial hypertension:,Adempas, as monotherapy or in combination with approved PAH treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:, idiopathic pulmonary arterial hypertension, heritable pulmonary arterial hypertension, pulmonary arterial hypertension associated with connective tissue diseases or, pulmonary arterial hypertension associated with congenital heart disease in adult patients with WHO functional Class II, lll or IV symptoms,Chronic thromboembolic pulmonary hypertension:,Adempas is indicated for the treatment of:,Persistent or recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or,inoperable CTEPH in adult patients with WHO functional Class II, lll or IV symptoms
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on December, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
This medicine is not considered safe during pregnancy. You should discuss this medicine with your doctor or pharmacist. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Pulmonary arterial hypertension:,Adempas, as monotherapy or in combination with approved PAH treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:, idiopathic pulmonary arterial hypertension, heritable pulmonary arterial hypertension, pulmonary arterial hypertension associated with connective tissue diseases or, pulmonary arterial hypertension associated with congenital heart disease in adult patients with WHO functional Class II, lll or IV symptoms,Chronic thromboembolic pulmonary hypertension:,Adempas is indicated for the treatment of:,Persistent or recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or,inoperable CTEPH in adult patients with WHO functional Class II, lll or IV symptoms
This medicine is not considered safe during pregnancy. You should discuss this medicine with your doctor or pharmacist. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Pulmonary arterial hypertension:,Adempas, as monotherapy or in combination with approved PAH treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:, idiopathic pulmonary arterial hypertension, heritable pulmonary arterial hypertension, pulmonary arterial hypertension associated with connective tissue diseases or, pulmonary arterial hypertension associated with congenital heart disease in adult patients with WHO functional Class II, lll or IV symptoms,Chronic thromboembolic pulmonary hypertension:,Adempas is indicated for the treatment of:,Persistent or recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or,inoperable CTEPH in adult patients with WHO functional Class II, lll or IV symptoms
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on December, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
This medicine is not considered safe during pregnancy. You should discuss this medicine with your doctor or pharmacist. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Pulmonary arterial hypertension:,Adempas, as monotherapy or in combination with approved PAH treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:, idiopathic pulmonary arterial hypertension, heritable pulmonary arterial hypertension, pulmonary arterial hypertension associated with connective tissue diseases or, pulmonary arterial hypertension associated with congenital heart disease in adult patients with WHO functional Class II, lll or IV symptoms,Chronic thromboembolic pulmonary hypertension:,Adempas is indicated for the treatment of:,Persistent or recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or,inoperable CTEPH in adult patients with WHO functional Class II, lll or IV symptoms
This medicine is not considered safe during pregnancy. You should discuss this medicine with your doctor or pharmacist. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Pulmonary arterial hypertension:,Adempas, as monotherapy or in combination with approved PAH treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:, idiopathic pulmonary arterial hypertension, heritable pulmonary arterial hypertension, pulmonary arterial hypertension associated with connective tissue diseases or, pulmonary arterial hypertension associated with congenital heart disease in adult patients with WHO functional Class II, lll or IV symptoms,Chronic thromboembolic pulmonary hypertension:,Adempas is indicated for the treatment of:,Persistent or recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or,inoperable CTEPH in adult patients with WHO functional Class II, lll or IV symptoms
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on December, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
This medicine is not considered safe during pregnancy. You should discuss this medicine with your doctor or pharmacist. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Pulmonary arterial hypertension:,Adempas, as monotherapy or in combination with approved PAH treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:, idiopathic pulmonary arterial hypertension, heritable pulmonary arterial hypertension, pulmonary arterial hypertension associated with connective tissue diseases or, pulmonary arterial hypertension associated with congenital heart disease in adult patients with WHO functional Class II, lll or IV symptoms,Chronic thromboembolic pulmonary hypertension:,Adempas is indicated for the treatment of:,Persistent or recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or,inoperable CTEPH in adult patients with WHO functional Class II, lll or IV symptoms
This medicine is not considered safe during pregnancy. You should discuss this medicine with your doctor or pharmacist. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Pulmonary arterial hypertension:,Adempas, as monotherapy or in combination with approved PAH treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:, idiopathic pulmonary arterial hypertension, heritable pulmonary arterial hypertension, pulmonary arterial hypertension associated with connective tissue diseases or, pulmonary arterial hypertension associated with congenital heart disease in adult patients with WHO functional Class II, lll or IV symptoms,Chronic thromboembolic pulmonary hypertension:,Adempas is indicated for the treatment of:,Persistent or recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or,inoperable CTEPH in adult patients with WHO functional Class II, lll or IV symptoms
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on December, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
This medicine is not considered safe during pregnancy. You should discuss this medicine with your doctor or pharmacist. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Pulmonary arterial hypertension:,Adempas, as monotherapy or in combination with approved PAH treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:, idiopathic pulmonary arterial hypertension, heritable pulmonary arterial hypertension, pulmonary arterial hypertension associated with connective tissue diseases or, pulmonary arterial hypertension associated with congenital heart disease in adult patients with WHO functional Class II, lll or IV symptoms,Chronic thromboembolic pulmonary hypertension:,Adempas is indicated for the treatment of:,Persistent or recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or,inoperable CTEPH in adult patients with WHO functional Class II, lll or IV symptoms
This medicine is not considered safe during pregnancy. You should discuss this medicine with your doctor or pharmacist. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Pulmonary arterial hypertension:,Adempas, as monotherapy or in combination with approved PAH treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:, idiopathic pulmonary arterial hypertension, heritable pulmonary arterial hypertension, pulmonary arterial hypertension associated with connective tissue diseases or, pulmonary arterial hypertension associated with congenital heart disease in adult patients with WHO functional Class II, lll or IV symptoms,Chronic thromboembolic pulmonary hypertension:,Adempas is indicated for the treatment of:,Persistent or recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or,inoperable CTEPH in adult patients with WHO functional Class II, lll or IV symptoms
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on December, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
This medicine is not considered safe during pregnancy. You should discuss this medicine with your doctor or pharmacist. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Pulmonary arterial hypertension:,Adempas, as monotherapy or in combination with approved PAH treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:, idiopathic pulmonary arterial hypertension, heritable pulmonary arterial hypertension, pulmonary arterial hypertension associated with connective tissue diseases or, pulmonary arterial hypertension associated with congenital heart disease in adult patients with WHO functional Class II, lll or IV symptoms,Chronic thromboembolic pulmonary hypertension:,Adempas is indicated for the treatment of:,Persistent or recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or,inoperable CTEPH in adult patients with WHO functional Class II, lll or IV symptoms
This medicine is not considered safe during pregnancy. You should discuss this medicine with your doctor or pharmacist. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
